ECM
AMPH icon

Everence Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Everence Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,470
Closed -$314K – 830
2024
Q3 		$314K Hold
6,470
– – 0.02% 568
2024
Q2 		$267K Hold
6,470
– – 0.02% 574
2024
Q1 		$284K Hold
6,470
– – 0.02% 583
2023
Q4 		$400K Hold
6,470
– – 0.03% 468
2023
Q3 		$298K Hold
6,470
– – 0.02% 552
2023
Q2 		$287K Hold
6,470
– – 0.02% 537
2023
Q1 		$243K Buy
+6,470
New +$212K 0.02% 615

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Everence Capital Management's AMPH Position: Q4 2024 in Review

Everence Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2024, closing a stake of 6,470 shares — an estimated $314K sold.

Everence Capital Management first reported a position in AMPH in Q1 2023 and held it in 7 quarters. The position peaked at $400K in Q4 2023. 263 funds tracked by Wall St. Rank hold AMPH as of Q4 2024.

  • Everence Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Everence Capital Management sold 6,470 Amphastar Pharmaceuticals shares in Q4 2024, an estimated $314K.
  • Everence Capital Management first reported a position in Amphastar Pharmaceuticals in Q1 2023 and held it in 7 quarters.
  • Everence Capital Management's Amphastar Pharmaceuticals position peaked at $400K in Q4 2023.
  • 263 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2024.

Based on Everence Capital Management's 13F filing for Q4 2024, filed 3 Jan 2025.